Adenosine deaminase deficiency (ADA-SCID)
Log in to starLast updated Nov 4, 2026
An infant with recurrent severe infections (pneumonia, chronic diarrhea, candidiasis) has absent T, B, and NK cells. Skeletal abnormalities are present on X-ray.
AR; ADA (adenosine deaminase, a purine degradation enzyme). Biallelic loss-of-function variants; the combined residual activity of the two alleles predicts severity.
Adenosine deaminase converts adenosine to inosine and deoxyadenosine to deoxyinosine, a housekeeping step of purine breakdown in every cell. In lymphoid cells the step is a detoxification: removing deoxyadenosine keeps the deoxyadenosine triphosphate (dATP) pool from expanding. When the enzyme is lost, deoxyadenosine and its nucleotides build up, and excess dATP interferes with DNA replication and drives apoptosis of lymphocytes, causing SCID. Non-immune problems occur too: rib and scapular changes (costochondral cupping), liver test abnormalities, and neurologic or behavioral problems including sensorineural hearing loss.
Most missense variants lie away from the active site and make an unstable protein; a few alter substrate or zinc binding. Residual activity from the two alleles together, ranked by expression studies, sets the phenotype:
- ADA-SCID: two null (deletion, frameshift, nonsense) or near-null missense alleles.
- ADA-related combined immunodeficiency: at least one allele expressing 0.1% to 0.6% activity.
- Partial deficiency, healthy: at least one allele keeping about 2% to 28%.
Red cell deoxyadenosine nucleotide levels track this order, and reversion mosaicism in lymphoid cells can soften the course. Treatment restores the enzyme systemically (PEGylated adenosine deaminase) or in lymphoid cells (HSCT, gene therapy).
Part of purine and pyrimidine metabolism.
Purine degradation (catabolism), which in lymphocytes doubles as detoxification.
adenosine, deoxyadenosine → adenosine deaminase (the block) → inosine, deoxyinosine → uric acid; blocked route: deoxyadenosine → dAMP → dADP → dATP
- Accumulates: adenosine and deoxyadenosine in dried blood spots (tandem mass spectrometry screening) and deoxyadenosine nucleotides (dATP) in red cells; low TRECs flag the lymphopenia on newborn screening.
- Missing: inosine and deoxyinosine from this step, and lymphocytes, which dATP kills.
- Workbook: 12.D. ADA deficiency (purine degradation)
- Severe combined immunodeficiency (SCID)
- T-B-NK- phenotype
- Costochondral abnormalities on X-ray
- Toxic accumulation of deoxyadenosine
- On RUSP (TREC-based SCID screening)
- Newborn screening flags low/absent TRECs (T-cell receptor excision circles), the universal SCID assay
- Lymphopenia with absent T, B, and NK cells (T-B-NK- pattern) on flow cytometry
- Low/absent erythrocyte ADA enzyme activity with elevated deoxyadenosine and dATP
- Confirmatory ADA molecular testing
- HSCT, gene therapy (Strimvelis), PEG-ADA enzyme replacement
ADA normally breaks down Adenosine to Inosine: when ADA is deficient, deoxyadenosine accumulates and is converted to increased dATP, which is lymphotoxic (toxic to both B and T cells, explaining the T-B-NK- SCID phenotype).
NBS: decreased TRECs: ADA-SCID is detected on newborn screening by decreased T-cell receptor excision circles (TRECs), the same assay used for all forms of SCID. One of the purine metabolism disorders (along with Lesch-Nyhan syndrome). Strictly, ADA is a purine catabolism (degradation) enzyme, whereas HPRT1 in Lesch-Nyhan is the classic salvage-pathway defect.